Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca Slips on Q3 Miss, Intends to Start Marking up Covid Vaccine Price

Published 11/12/2021, 06:50 AM
Updated 11/12/2021, 06:53 AM
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – ADRs of AstraZeneca (NASDAQ:AZN) fell more than 4% in Friday’s premarket trading as the company’s third-quarter profit fell short of estimates.

Disappointing sales in China from its top-selling cancer drug Tagrisso, along with the high costs of integrating its recent acquisition, Alexion (NASDAQ:ALXN), both weighed on the bottom line, which was only partially offset by the start of profits booked from its Covid-19 vaccine, Vaxzevria.

Vaxzevria achieved $1.05 billion in sales in the quarter. The company had previously said it would end its policy of selling the drug at cost price once the pandemic emergency was over. It will still continue to sell the drug at cost to developing nations. Its ability to generate returns on Vaxzevria, meanwhile, is likely to be constrained by higher the loss of market share to vaccines produced by Pfizer/BioNTech and Moderna (NASDAQ:MRNA), which have shown higher efficacy rates.

Pfizer (NYSE:PFE) expects its Covid vaccine to bring in $36 billion in sales this financial year, although Moderna was recently forced to revise down its sales guidance due to manufacturing problems. It has also been partially suspended in various countries due to suspected links to heart inflammation in some age groups.

The company’s profit per share in the September quarter came in at $1.08 per share. Total product sales jumped 47% to $9.74 billion. Total revenue was $9.86 billion.

It now expects its annual revenue, including from Covid vaccine, to grow by around 27%. It expects EPS to be around $5.23.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.